B. Kusserow Paul - Jan 6, 2022 Form 4 Insider Report for AMEDISYS INC (AMED)

Role
CEO and Chairman of the Board, Director
Signature
/s/ Jennifer R. Guckert, pursuant to a power of attorney
Stock symbol
AMED
Transactions as of
Jan 6, 2022
Transactions value $
$0
Form type
4
Date filed
1/10/2022, 07:00 AM
Previous filing
Jan 4, 2022
Next filing
Feb 22, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMED Common Stock Gift $0 -17.6K -17.4% $0.00 83.8K Sep 15, 2021 By Trust
transaction AMED Common Stock Award $0 +17.3K +5.22% $0.00 350K Jan 6, 2022 Direct F1
holding AMED Common Stock 621 Jan 6, 2022 Through 401(k) Plan F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMED Restricted Stock Unit (Performance-Based Vesting) Award $0 +5.78K $0.00 5.78K Jan 6, 2022 Common Stock 5.78K Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Issuer awarded the Reporting Person 17,330 time-based Restricted Stock Units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock, and will vest on January 6, 2023, subject to certain vesting provisions as set forth in the award agreement for the RSUs.
F2 The information in this report is based on a plan statement dated as of September 30, 2021.
F3 The RSUs awarded are subject to performance-based vesting based on achievement of an identified performance goal for 2022 and will vest after the end of the 2022 fiscal year, based on the certification by the Compensation Committee of the achievement of the identified performance goal for 2022, subject to certain vesting provisions as set forth in the award agreement for the RSUs.

Remarks:

CEO and Chairman of the Board